Untitled

Tuberculosis infection is of paramount relevance to the IBD population given the frequent use of immunosuppressive medications. Diagnosing latent tuberculosis infection provides a window of opportunity for treatment. The risks of reactivation with immunosuppressive therapy must be weighed against the risk of side effects, inconvenience of treatment and costs. It is important to consider infectious diseases physician input for decision making.